A PYMNTS Company

AbbVie Dodges Antitrust Challenge to Its Humira ‘Patent Thicket’

By  |  June 8, 2020

AbbVie Inc., Amgen Inc., a Samsung subsidiary, and Novartis unit Sandoz Inc. don’t have to face antitrust claims over patent infringement settlements that delayed generic competition for the blockbuster arthritis drug Humira, a Chicago federal judge ruled Monday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    “AbbVie has exploited advantages conferred on it through lawful practices,” Judge Manish S. Shah wrote. “To the extent this has kept prices high for Humira, existing antitrust doctrine does not prohibit it.”

    The proposed class action accused AbbVie of shielding its monopoly on Humira—the country’s top-selling prescription drug, with $20 billion a year in global sales—with more than 100 patents, including many that won’t expire until 2034. Humira injections cost about $4,500 a month.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.